Search

Your search keyword '"Matthews, Gail V ' showing total 867 results

Search Constraints

Start Over You searched for: Author "Matthews, Gail V Remove constraint Author: "Matthews, Gail V
867 results on '"Matthews, Gail V '

Search Results

1. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

2. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

4. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

6. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

7. The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC

9. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT

10. Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study

12. Reinfection incidence and risk among people treated for recent hepatitis C virus infection

14. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

17. Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study.

18. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

19. Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023).

20. High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study

22. Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia

23. High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells

24. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

25. Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study

26. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

27. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales

28. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort

31. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

32. Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

33. One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review

34. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

35. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

36. Cure and Control: What Will It Take to Eliminate HCV?

37. Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study

39. Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020

40. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

41. Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)]

43. Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020

44. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

45. Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population‐based study.

46. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

47. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

48. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

50. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Catalog

Books, media, physical & digital resources